Harrow, Inc. (HROW)
| Market Cap | 1.37B -4.8% |
| Revenue (ttm) | 275.59M +21.1% |
| Net Income | -37.23M |
| EPS | -1.00 |
| Shares Out | 37.49M |
| PE Ratio | n/a |
| Forward PE | 28.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,290 |
| Open | 37.22 |
| Previous Close | 37.27 |
| Day's Range | 36.28 - 37.45 |
| 52-Week Range | 28.54 - 54.85 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 67.50 (+85.13%) |
| Earnings Date | Aug 10, 2026 |
About HROW
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for p... [Read more]
Financial Performance
In 2025, Harrow's revenue was $272.30 million, an increase of 36.41% compared to the previous year's $199.61 million. Losses were -$5.14 million, -70.60% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price target is $67.5, which is an increase of 85.13% from the latest price.
News
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients...
Harrow Earnings Call Transcript: Q2 2026
Revenue grew 11% YoY in Q2 to $70.7M, with strong sequential growth and improved product economics. Multiple growth drivers, including VEVYE, IHEEZO, and TRIESENCE, are set for accelerated H2 performance. Full-year guidance of $350–$365M revenue and $80–$100M adjusted EBITDA reiterated.
Harrow Earnings release: Q2 2026
Harrow released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Harrow Quarterly report: Q2 2026
Harrow has published its Q2 2026 quarterly earnings report on August 11, 2026.
Harrow Slides: Q2 2026
Harrow has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
Harrow reports Q2 EPS (46c), consensus (24c)
Reports Q2 revenue $70.66M, consensus $70.35M. “We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives. The second half…
Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M
Harrow (HROW) announced that it has entered into a definitive agreement to acquire Tyrvaya nasal spray 0.03 mg from Viatris (VTRS). Tyrvaya is a cholinergic agonist indicated for the treatment…
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a de...
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026
Harrow and Samsung Bioepis present interim BYOOVIZ post-marketing data
Harrow (HROW) and Samsung Bioepis presented interim data from a post-marketing surveillance study on SB11, a biosimilar referencing Lucentis, at the Annual Meeting of the American Society of Retina Sp...
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ®) to reference ranibizumab In treatment-naïve patients, SB11 provided functiona...
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three stu...
Harrow announces commercial launch of Byooviz in the U.S.
Harrow (HROW) announced the commercial launch of Byooviz, an FDA-approved biosimilar referencing Lucentisi and developed by Samsung Bioepis.
Harrow announces commercial launch of BYOOVIZ in U.S.
Harrow (HROW) announced the commercial launch of BYOOVIZ, an FDA-approved biosimilar referencing LUCENTISi and developed by Samsung Bioepis. The launch follows Harrow’s exclusive U.S. commercializatio...
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). ...
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (c...
Harrow Transcript: 46th Annual William Blair Growth Stock Conference
Strong revenue and EBITDA growth are projected through 2028, driven by innovative ophthalmic products, expanded sales force, and new launches like MELT and biosimilars. Key products are rapidly gaining market share and displacing legacy therapies, with strategic reimbursement and clinical initiatives supporting continued acceleration.
Harrow Slides: 46th Annual William Blair Growth Stock Conference
Harrow has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Harrow to Present at William Blair's 46th Annual Growth Stock Conference
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present a...
Harrow CEO buys $302K, CFO buys $104.7K in common stock
In regulatory filings, Harrow (HROW) disclosed that its CEO, Mark Baum, bought 10,000 shares of common stock and CFO Andrew Boll bought 3,500 shares of common stock on May 14th…
Harrow price target lowered to $60 from $65 at B. Riley
B. Riley lowered the firm’s price target on Harrow (HROW) to $60 from $65 and keeps a Buy rating on the shares. Harrow saw Q1 results overshadowed by weaker VEVYE…
Harrow price target lowered to $88 from $91 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse lowered the firm’s price target on Harrow (HROW) to $88 from $91 and keeps an Overweight rating on the shares.
Harrow Earnings Call Transcript: Q1 2026
Q1 revenue was $44.2M, impacted by an $8M VEVYE gross-to-net adjustment, but demand for key products remains strong. Full-year guidance of $350M–$365M is reaffirmed, with sequential growth and new product launches expected to drive a stronger second half.
Harrow Earnings release: Q1 2026
Harrow released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.